Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registryPasquale Paolisso, Carmine Pizzi, Luca Bergamaschi et al.|Cardiovascular Diabetology|2022Cited by 206
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT RegistryPasquale Paolisso, Emanuele Barbato, Luca Bergamaschi et al.|Pharmacological Research|2022Cited by 146
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Marco Valgimigli, Dominick J. Angiolillo et al.|Journal of the American College of Cardiology|2023Cited by 119
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugsGiuseppe Patti, Ilaria Cavallari, Felicita Andreotti et al.|Nature Reviews Cardiology|2018Cited by 116
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosisCelestino Sardu, Raffaele Marfella, Maria Consiglia Trotta et al.|Cardiovascular Diabetology|2023Cited by 106